ResMed Inc. vs Atlassian Corporation PLC — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Atlassian Corporation PLC trades at $178.15 (market cap $44.66B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap, and ResMed Inc. pays a 1.19% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| RMD | TEAM | |
|---|---|---|
Market Cap | $31.89B | $44.66B |
Sector | Health | Technology |
52-Week High | $283.28 | $194.68 |
52-Week Low | $182.82 | $57.15 |
Enterprise Value | $31.24B | $44.65B |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Atlassian (TEAM) trades at $176.42, down 6.94% on the day, despite strong recent performance with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with support at $173 and resistance at $182. Revenue growth continues at $5.22B (2025) with improving margins, though the company remains unprofitable with a -0.82% net income margin. Analyst consensus is strongly bullish with 30 buy ratings and a $179.81 price target, while recent news highlights AI integration driving cloud growth.
TEAM presents a growth-oriented investment with significant upside potential from AI adoption and market expansion, but carries risks from persistent losses, premium valuation (P/S 6.98), and insider selling. The path to profitability remains key, with projected net losses narrowing to -$54M in 2026. Investors should weigh strong analyst support against high execution demands in a competitive SaaS landscape.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →